Contact us
5 phases of SaMD development _2
5 phases of SaMD development _3
Back to Insights

SaMD

Winning in Medical Devices sector: Key Takeaways from MedTech Strategist in Dublin 2024

Share this article

May 16, 2024

6 min read

samd series | author

Weronika Michaluk

Digital Health Principal
SaMD Lead at HTD Health

The 10th MedTech Strategist Innovation Summit held in Dublin in April 2024 brought together industry leaders, innovators, and investors to discuss the future of medical technology. The conference provided valuable insights into the integration of artificial intelligence (AI) in patient care and effective strategies for commercializing medical technologies.

The Dublin Innovation Summit buzzed with groundbreaking ideas! Here are 3 insights you don’t want to miss. Let’s dive in!

Get the latest news about Software for Medical Devices from our experts.

Newsletter terms

Revolutionizing Patient Care with AI

One of the panels covered how AI is revolutionizing medical diagnostics and patient care. A nice example is Neuro Event Labs, which has developed a sophisticated system that automatically examines video and audio at a patient’s bedside to assist with epilepsy care. This innovation marks a significant leap forward, illustrating the rapid pace at which AI is advancing in the medtech sector. The discussion highlighted that thanks to new regulations, there is now greater clarity on how to effectively utilize AI’s capabilities in healthcare.

The panel also highlighted the critical role of robust data management. Companies like Deciphex are leading the way by efficiently gathering and organizing data, which is essential for creating reliable AI tools. This great data handling is foundational for building trustworthy AI applications. However, the process of collecting and processing this data can be expensive. Despite these challenges, smaller companies are finding inventive ways to disrupt the industry.

Whats more, the discussions at the conference shed light on the broader implications of AI in healthcare. The integration of AI not only enhances diagnostic accuracy but also improves patient outcomes by enabling more personalized care. The regulatory advancements are crucial as they provide a framework that ensures the safe and effective deployment of AI tools. This regulatory clarity encourages more companies to invest in AI, fostering innovation and competition in the medtech field.

Another great discussion at the conference focused on “Charting the Path for Successful Commercialization Strategies.” The panel featured world-class leaders such as Virginia Giddings from Edwards Lifesciences and Kip Roberts from Medtronic, who shared their valuable insights. A key piece of advice they offered was the importance of demonstrating how a product has been made less risky for investors, rather than just highlighting its potential for high profitability. During the panel, it was emphasized that “If you want to get the attention of the strategics, instead of showing them a graph of revenues shooting up north of $1 billion, show a de-risking curve.” This approach underscores the significance of risk management in attracting strategic partners and investors.

Panelists elaborated on the practical steps companies can take to de-risk their products. This includes rigorous testing and validation, securing regulatory approvals, and establishing strong intellectual property protections. By focusing on these areas, companies can build confidence among investors that the potential challenges and uncertainties associated with their products have been addressed. This strategy not only makes the investment opportunity more attractive but also demonstrates a company’s commitment to long-term success and sustainability.

Moreover, the panelists discussed the broader implications of de-risking strategies in the commercialization process. They pointed out that in today’s competitive market, simply projecting high revenues is not sufficient to secure investment. Investors are increasingly looking for evidence that companies have taken proactive steps to mitigate risks. This includes having a clear regulatory pathway, robust clinical data, and a well-defined market entry strategy. By presenting a comprehensive de-risking plan, companies can differentiate themselves from competitors and increase their chances of securing funding and strategic partnerships.

In addition to financial considerations, the panel also highlighted the importance of aligning de-risking efforts with the overall business strategy. This involves continuous monitoring and assessment of potential risks throughout the product development lifecycle. Companies should be prepared to adapt their strategies based on evolving market conditions and regulatory landscapes. By maintaining a proactive and flexible approach to risk management, companies can better navigate the complexities of commercialization and achieve sustainable growth.

Get the latest news about SaMD from our experts.

Newsletter terms

“FDA Inspections: Getting Prepped and Avoiding Pitfalls”

Another interesting thing discussed was the strategic shift of companies towards the US market, driven by the complexities of the Medical Device Regulation (MDR) in Europe. This “FDA First” strategy is gaining traction due to the clearer regulatory pathways in the United States, making the FDA a more appealing entry point for companies looking to navigate the market effectively. Companies are finding that the streamlined processes and predictable timelines provided by the FDA can significantly reduce the time and resources needed to bring medical devices to market.

The concluding panel, titled “FDA Inspections: Getting Prepped and Avoiding Pitfalls,” moderated by David Filmore, highlighted the critical importance of being well-prepared for FDA scrutiny. Experts like Nancy Lince and Jamie Harris shared their valuable insights on developing effective quality systems tailored to meet organizational needs. They emphasized the importance of understanding the FDA’s expectations and requirements to create robust quality management systems. Additionally, the panelists discussed the necessity of thorough documentation and regular internal audits to ensure ongoing compliance.

The experts also highlighted the benefits of early and continuous communication with the FDA throughout the product development process. Engaging with the FDA early on can help companies identify potential issues and address them proactively, thus avoiding delays and costly mistakes. The panel concluded with practical tips for navigating FDA inspections, such as conducting mock inspections and training staff to handle regulatory inquiries confidently. These strategies not only help in passing inspections but also build a culture of quality and compliance within the organization. Overall, the session underscored that meticulous preparation and strategic planning are essential for successfully navigating FDA inspections and achieving market success in the US.

Conclusion

The 10th Annual Innovation Summit in Dublin has clearly demonstrated that the future of patient care is linked to advancements in AI and effective strategies for navigating the complex medtech commercialization landscape. As the industry continues to evolve, staying informed and prepared for regulatory challenges will be key to success. The insights shared during this conference serve as a valuable guide for any stakeholder in the medtech industry aiming to leverage technology to improve healthcare outcomes and achieve business success.

If you are looking into developing software as a medical device or are looking for regulatory or quality support, reach out to info@htdhealth.com and we will be happy to help you!

Other content you may be interested in

View all articles

May 09, 2024

12 min read

SaMD

How to choose best partner for medical device software development?

Read more

Apr 18, 2024

SaMD

3 Critical Steps for Efficient Medical Device Software Development

Read more

Apr 04, 2024

9 min read

SaMD

Achieving ISO 13485: HTD’s proven audit checklist

Read more